Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
Feb 2, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Jan 27, 2022

Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Jan 20, 2022

Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Jan 11, 2022

Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook

Dec 21, 2021

Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer

Dec 15, 2021

Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting

Dec 10, 2021

Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium

Nov 19, 2021

Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium

Nov 5, 2021

Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results

Nov 3, 2021

Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...58
    © 2022 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap